Open Innovation: Public-private partnership tackles antibiotic threat

by | May 28, 2012

This is a great example of innovation in the pharmaceutical industry working alongside public research bodies. Not driven by profit, this collaboration has the greater good as its main goal.

GlaxoSmithKline and AstraZeneca are teaming with public research bodies in Europe to tackle the threat of antibiotic resistance and stimulate further research.

Pharmacetuical companies will work alongside public research labs to tackle antibiotic resistance. Photo: 2edeveloperteam/Flickr.

Pharmacetuical companies will work alongside public research labs to tackle antibiotic resistance. Photo: 2edeveloperteam/Flickr.

In an effort to improve the current understanding of antibiotic resistance, the pharmaceutical and biotechnology companies will carry out clinical trials and design and develop new drugs to combat this threat.

The research is a part of the European Commission’s Action Plan against the rising threats from Antimicrobial Resistance.

World Pharma News reports that the World Health Organization had declared the pool of any potential antibiotics as “virtually dry”. The much-needed study, called NewDrugs4BadBugs, will be a shot in the arm for the future discovery and development of new medicines.

Antibiotic resistance is increasingly become a global concern. Research and development has stalled somewhat over the past 15 years. It is a mammoth task, scientifically, to find new agents that target bacteria and this combined with regulatory red-tape and lack of commercial enticements meant that research in this area has almost come to a standstill.

We often speak of open innovation – this is a shining example of global innovation powered by open communication, and also an excellent example of innovation in the pharmaceutical industry.

Read the story here.

Jeffrey Tobias

About Jeffrey Tobias

Dr Tobias is an accomplished innovation consultant and entrepreneurship strategist, drawing expertise from the academic, entrepreneurial and corporate worlds. Jeffrey’s commercial and business experience is particularly focussed on lean startup, design thinking and leadership. Prior to The Strategy Group, Jeffrey was Cisco’s Global Lead for Innovation in the Internet Business Solutions Group helping Fortune Global 500 companies improve customer experience and grow revenue by transforming how they do business.
Jeffrey is a professor of innovation and entrepreneurship teaching MBA students at the Australian Graduate School of Business at the University of New South Wales. An active angel investor, Jeffrey is on the board of various well-known startups.

View All Posts

Managing Director, The Strategy Group

Dr Tobias is an accomplished innovation consultant and entrepreneurship strategist, drawing expertise from the academic, entrepreneurial and corporate worlds. Jeffrey’s commercial and business experience is particularly focussed on lean startup, design thinking and leadership. Prior to The Strategy Group, Jeffrey was Cisco’s Global Lead for Innovation in the Internet Business Solutions Group helping Fortune Global 500 companies improve customer experience and grow revenue by transforming how they do business.
Jeffrey is a professor of innovation and entrepreneurship teaching MBA students at the Australian Graduate School of Business at the University of New South Wales. An active angel investor, Jeffrey is on the board of various well known startups. Jeffrey’s corporate background includes leading global innovation strategy at Cisco, working with large corporates such as Adobe, Westpac, Telstra, Woolworths, and Perpetual.

Need help to get your business to the next level?

More related articles on innovation

Share This